-
Mashup Score: 9Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents - 1 month(s) ago
The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents,…
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9Exploring Emerging Approaches in Acute Myeloid Leukemia - 3 month(s) ago
Drs DiNardo, Erba, and Zeidan discuss recent data on the most promising emerging therapies in acute myeloid leukemia (AML).
Source: www.medscape.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0SLS009 granted orphan drug designation by the U.S. FDA - 5 month(s) ago
On October 10, 2023, the U.S. FDA granted orphan drug designation to SLS009, a novel and highly selective CDK9 inhibitor, for the treatment of patients with AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Transplant Sessions: Should patients with AML receive treatment before transplantation? | VJHemOnc - 6 month(s) ago
Welcome to the Transplant Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). In this session, leading experts Johannes Schetelig, MD, DKMS Group and TU Dresden, Dresden, Germany, and Gesine Bug, MD, Goethe University Frankfurt, Frankfurt, Germany, discuss whether patients with acute myeloid leukemia (AML) should receive treatment before stem cell transplantation (SCT), which was presented and debated at the 2023 SOHO Annual Meeting. The experts further discuss findings
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
PURPOSE Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or refractory FLT3-mutated AML. We investigated the safety, tolerability, and efficacy of gilteritinib incorporated into intensive induction and consolidation chemotherapy, and as maintenance therapy for adult patients with newly diagnosed, nonβfavorable-risk AML. METHODS In this phase IB study (2215-CL-0103; ClinicalTrials.gov identifier: NCT02236013), 103 participants were screened and 80 were allocated to treatment. The study was divided into four parts: dose escalation, dose expansion, investigation of alternate anthracycline and gilteritinib schedule, and continuous gilteritinib during consolidation. RESULTS After dose escalation, 120 mg gilteritinib once daily was chosen for further study. There were 58 participants evaluable for response at this dose, 36 of whom harbored FLT3 mutations. For participants with FLT3-mutated AML, the composite complete response (CRc) rate was 89% (83% were conventiona
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Spotlight on lower-risk MDS - 6 month(s) ago
In this Spotlight On Lower-risk MDS, learn about MDS risk stratification & classification, recognizing ESA failure, and treatment beyond ESAs
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Editorial theme | Navigating the recent updates to the classification of AML β the International Consensus Classification - 6 month(s) ago
In the first article of our editorial theme on the latest updates in the classification of AML, we focus on the International Consensus Classification and its key differences from the WHO classification.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Editorial theme | Navigating the latest updates in classification systems for AML: The 2022 ELN recommendations - 6 month(s) ago
During the EHA 2023, Hartmut DΓΆhner and Gert Ossenkoppele discussed the latest updates to the ELN 2022 recommendations and classification of AML, which we are pleased to summarize below.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
As part of our editorial theme on navigating the latest updates in the classification systems for AML, we summarize two presentations from #EHA2023 discussing the latest updates to the 2022 ELN recommendations & the classification of AML π https://t.co/Cdl3KIARkk. #leusm #AMLsm https://t.co/LN2ibbTycN
-
-
Mashup Score: 0iwAL 2023 Session III: The relevance of TP53 mutation in AML - 6 month(s) ago
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
On September 27, 2023, it was announced that the first two patients had received SMART101 in the multicenter, open-lab, dose-escalation, phase I/II ReSET-02 trial.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
π¨ NEWS π¨ First two patients dosed in the phase I/II ReSET-02 trial to assess the safety & efficacy of SMART101, an allogeneic cell therapy, in patients with AML who have received allo-HSCT with post-transplant cyclophosphamide π https://t.co/yR7jQMYrqk #AMLsm #leusm #MedNews https://t.co/YCnXRkUqGx
-
Targeted agents, including menin inhibitors, are showing promise in AML. Tune in to this week's podcast to find out more about these agents & the AUGMENT-101 & KOMET-008 trials: π§ https://t.co/UPsyGCewce Ft. Mark Levis, @GhayasIssa, Ibrahim Aldoss & Aaron Goldberg #AMLsm https://t.co/krSD1cnkSx